Silo pharma set to acquire exclusive licensing for promising alzheimer's disease therapeutic

Spc-14 shows cognitive and stress reduction benefits in preclinical models sarasota, fl, april 10, 2024 (globe newswire) --  silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has exercised its option to license alzheimer's disease (ad) therapeutic spc-14 from columbia university, pursuant to a sponsored research and option agreement established in 2021. under the terms of the license agreement currently in process, silo will be granted an exclusive license to further develop, manufacture, and commercialize spc-14 worldwide upon consummation of such agreement.
SILO Ratings Summary
SILO Quant Ranking